Patents by Inventor Michael Klagsbrun

Michael Klagsbrun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20230256053
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: April 6, 2023
    Publication date: August 17, 2023
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20190388505
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: September 5, 2019
    Publication date: December 26, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • Methods and compositions for immunomodulation
    Patent number: 10456445
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 29, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. Briscoe, Michael Klagsbrun, Sarah Bruneau, Nora Kochupurakkal, Hironao Nakayama
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20170100456
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 13, 2017
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF
    Publication number: 20150025224
    Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
    Type: Application
    Filed: October 1, 2014
    Publication date: January 22, 2015
    Inventors: Michael Klagsbrun, Shay Soker, Harry Hua-Quan Miao, Seiji Takashima
  • Pharmaceutical compositions comprising peptide antagonists of vascular endothelial growth factor
    Patent number: 8889620
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: November 18, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker
  • SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF
    Publication number: 20140178986
    Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 26, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael Klagsbrun, Shay Soker, Michael L. Gagnon
  • ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF
    Publication number: 20140056872
    Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
    Type: Application
    Filed: October 29, 2012
    Publication date: February 27, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael Klagsbrun, Shay Soker, Harry Hua-Quan Miao, Seiji Takashima
  • Soluble inhibitors of vascular endothelial growth factor and use thereof
    Patent number: 8529905
    Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: September 10, 2013
    Assignee: Childrens's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker, Michael L. Gagnon
  • PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND METHODS OF USE THEREOF
    Publication number: 20130230504
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Application
    Filed: February 3, 2012
    Publication date: September 5, 2013
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael KLAGSBRUN, Shay SOKER
  • Peptide antagonists of vascular endothelial growth factor and methods of use thereof
    Patent number: 8153585
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: April 10, 2012
    Assignee: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker
  • METHOD TO PROGNOSE RESPONSE TO ANTI-EGFR THERAPEUTICS
    Publication number: 20110052570
    Abstract: The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at risk for developing cancer with an EGFR targeting treatment and methods to screen for an EGFR targeting treatment.
    Type: Application
    Filed: October 24, 2006
    Publication date: March 3, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael Klagsbrun, Dhara N. Amin, Kyoko Hida
  • ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF
    Publication number: 20110002919
    Abstract: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
    Type: Application
    Filed: March 17, 2010
    Publication date: January 6, 2011
    Applicant: Children's Medical Center
    Inventors: Michael Klagsbrun, Shay Soker, Harry Hua-Quan Miao, Seiji Takashima
  • SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF
    Publication number: 20100267140
    Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 21, 2010
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael KLAGSBRUN, Shay SOKER, Michael L. GAGNON
  • PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
    Publication number: 20100249025
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Application
    Filed: July 14, 2008
    Publication date: September 30, 2010
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael KLAGSBRUN, Shay SOKER
  • Soluble inhibitors of vascular endothelial growth factor and use thereof
    Patent number: 7736655
    Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: June 15, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker, Michael Gagnon
  • Antagonists of neuropilin receptor function and use thereof
    Patent number: 7731959
    Abstract: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: June 8, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker, Hua-Quan Miao, Seiji Takashima
  • Soluble inhibitors of vascular endothelial growth factor and use thereof
    Publication number: 20080261867
    Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
    Type: Application
    Filed: August 17, 2007
    Publication date: October 23, 2008
    Applicant: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker, Michael L. Gagnon
  • Peptide antagonists of vascular endothelial growth factor
    Patent number: 7414027
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: August 19, 2008
    Assignee: Childen's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker
  • Antagonists of neuropilin receptor function and use thereof
    Publication number: 20080076906
    Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer particularly, metastatic cancer and angiogenic diseases.
    Type: Application
    Filed: August 16, 2007
    Publication date: March 27, 2008
    Applicant: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker, Hua-Quan Miao, Seiji Takashima